Introduction 59 60
Despite its widespread use, patients receiving efavirenz-containing therapy frequently report central 61 nervous system (CNS) disturbances. Symptoms of efavirenz-associated adverse drug reactions 62 (ADRs) occur with a high frequency and can include depression, anxiety, abnormal dreams and 63 hallucinations (1). The majority of patients report development of CNS disorders shortly after 64 commencing efavirenz therapy with symptoms dissipating during the initial months of therapy. A 65 minority of patients continue to experience symptoms for the duration of efavirenz use (2). More 66 recently, efavirenz CNS ADRs have been shown to have more long-term effects (3). 67
68
In addition to the negative impact on the quality of the patient's life, CNS ADRs may also lead to a 69 decrease in patient adherence. Poor patient adherence to antiretroviral medication is a major concern, 70 in particular drugs displaying a low genetic barrier to resistance such as efavirenz (4). The impact of 71 CNS side effects on patient adherence is not clearly defined. Some previous studies indicate that 72 patients demonstrate tolerance to CNS side effects with minimal impact on patient adherence (5, 6) . 73
However, a recent study demonstrated 60% of patients reported CNS side effects as the primary 74 reason for discontinuation vs. 3% of patients receiving alternative antiretroviral therapies (3). 75
76
There is a paucity of information regarding distribution of efavirenz into brain tissue. Due to 77 impracticalities in obtaining brain tissue from patients, some groups have used concentrations in 78 cerebrospinal fluid (CSF) as a surrogate for brain concentrations. The majority of pharmacokinetic 79 (PK) studies have focused on describing efavirenz plasma concentrations and elucidating genetic 80 factors that contribute to the variability in efavirenz PK or genetic associations to predict patients at 81 risk of developing CNS toxicity (1, 7, 8) . However there are a few small studies that investigated 82 efavirenz PK in both plasma and CSF. CSF concentrations have been shown to be much lower 83 (around 0.5%) than plasma. However, even at 0.5% of the plasma concentration efavirenz 84 concentrations in the CSF exceed the IC 50 of efavirenz for wild type HIV (9). 85 on November 7, 2016 by University of Liverpool Library http://aac.asm.org/
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Male Wistar rats (Charles River UK) weighing 180 -220 g on arrival were used for PK analysis of 112 efavirenz. Food and water were provided ad libitum. Following completion of the dosing all animals 113 were sacrificed using an appropriate schedule 1 method (via exposure to CO 2 in a rising 114 concentration). All animal work was conducted in accordance with the Animals (Scientific 115 Procedures) Act 1986 (ASPA), implemented by the United Kingdom Home Office. 116
117

Drug Treatment 118
Eight male Wistar rats were dosed with efavirenz (10 mg kg -1 , 2 mL kg -1 0.5% methylcellulose in 119 dH 2 O) based on individual weight taken prior to dosing. The selected dose was based on scaling 120 down the dose administered to adult humans (600mg once daily given to an adult weighing 60/70kg). 121
The dose was also selected as it has been administered to rats previously in a study examining the 122 anxiogenic effects where it was shown to induce anxiety in Wistar rats (15). Dosing was 123 administered once daily via oral gavage over 5 weeks. The animals were terminated (via exposure to 124 CO 2 in a rising concentration) 2 hours after the final dose and blood was collected via cardiac 125 puncture. Blood samples were centrifuged at 2000g for 10 minutes at 4°C to separate plasma. Plasma 126 was immediately frozen at -80°C and stored for later analysis. Brain tissue was also collected and 127 following washing in phosphate buffered saline for 30 seconds 3 times, immediately stored at -30°C 128 for analysis. 129
130
Rapid Equilibrium Dialysis 131
The protein binding of efavirenz in brain tissue was performed using rapid equilibrium dialysis 132 (RED) as described by Liu et al. (16) precipitation detailed in the previous section. Recovery was tested at 3 levels (400 ng mL -1 100 ng 155 mL -1 and 20 ng mL -1 ). Mean recovery was 95% (standard deviation 8.9) and 91% (standard deviation 156 7.8) for plasma and brain, respectively. Samples generated from the RED experiment were pretreated 157 with 20% ACN (PBS and Sorensons buffer were spiked with 20% ACN in order to aid efavirenz 158 solubility in these matrices) and mean recovery was 84% (SD% 11.6) . 178.1 and 198.1). A stock solution of 1 mg mL -1 efavirenz was prepared in methanol and stored at 165 4°C until use. A standard curve was prepared in plasma by serial dilution from 500 ng mL -1 to 1.9 ng 166 mL -1 and an additional blank solution was also used. 167
168
Chromatographic separation was achieved using a multi step gradient with a Hypersil gold C-18 169 column (Thermo scientific) using mobile phases A (100% H 2 O, 5mM NH 4 HCO 2 ) and B (100% 170 ACN, 5mM NH 4 HCO 2 ). Chromatography was conducted over 8.55 minutes at a flow rate of 300 µl 171 min -1 . At the start of each run, mobile phase A was 90% until 0.1 minutes when mobile phase B was 172 increased to 86% at 0.5 minutes. Mobile phase B was then gradually increased to 92% over 4.5 173 minutes. Mobile phase B was then increased to 97% at 5.1 minutes which was held until 6 minutes. 174
Mobile phase A was then increased to 90% and held till the termination of the run at 8 minutes. 175
Inter-and intra-assay variance in accuracy and precision were <15%. 176
177
PBPK parameters 178
The full body PBPK model used here has been previously published using equations from the physB 179 model ( 
Simulation Design 254
A virtual cohort of 100 patients was generated and a once-daily dose of efavirenz (600 mg) was 255 simulated over 5 weeks. Patient age (minimum 18 maximum 60), weight (minimum 40kg, maximum 256 100kg), height (minimum 1.5 meters maximum 2.1 meters) and body mass index (minimum 18, 257 maximum 30) were generated from random normally distributed values. The PK in plasma, CSF and 258 brain tissue were recorded during the final 24 hours at steady state. Plasma and CSF PK simulations 259 were compared with previous data generated from clinical trials. Brain tissue to plasma ratios were 260 also calculated and compared to data generated in rodents. 261
262
Materials 263
Male Wistar rats were purchased from Charles River (Oxford, UK). Efavirenz powder (>98% pure) 264 was purchased from LGM Pharma Inc (Boca Raton, USA). All other consumables were purchased 265 from Sigma Aldrich (Dorset, UK). 266
267
Results
268
The protein binding of efavirenz in brain tissue was determined using rapid equilibrium dialysis. The 269 mean (± standard deviation) concentration of efavirenz detected in the receiver chamber was 209.7 ± 270 33.4 ng mL -1 , and 165 ± 22.0 ng mL -1 10% and 20% brain homogenate respectively. The fraction 271 unbound in brain tissue (fu Br ) was calculated to be 0.00181 and 0.00212 in 10% and 20% brain 272 homogenate, respectively. The average fu Br was 0.00197. 273
274
Following 5 weeks of oral dosing of efavirenz (10 mg kg -1 ), the median plasma concentration of 275 efavirenz in rats was 69.7 ng mL -1 (IQR 44.9 -130.6). Median efavirenz concentrations in brain 276 tissue were 702.9 ng mL -1 (IQR 475.5 -1018.0). The median tissue to plasma ratio was 9.5 (IQR 7.0 277 -10.9). 
Comparison with clinical data 304
The simulated PK parameters in plasma produced by the model were in agreement with data 305 published from human trials and population PK studies (popPK). Table 2 shows the results from the 306 simulation and a number of clinical studies and popPK studies. The mean/median observed plasma 307 concentrations of EFV ranged from 1973 ng mL -1 to 3180 ng mL -1 (9, 23-26). Simulated Cl, V SS and 308 K a were 1.04 fold, 1.28 fold and 0.6 fold different compared to observed data (26). The average 309 simulated CSF concentrations were 49.9 ng mL -1 (IQR 36.6-69.7) compared to a range of 11.1 ng 310 mL -1 to 16.3 ng mL -1 observed in previously published clinical studies (9, 23). The presented data show that the PBPK model predicts efavirenz to accumulate in the brain in 315 concentrations that far exceed those in the CSF. Human CSF concentrations were gathered from 316 relatively small cohorts (Best N=80, Yilmaz N=1 and Tashima N=10) and may not fully represent 317 CSF concentrations larger populations. Indeed, concentrations of efavirenz in the brain were 318 predicted to exceed even plasma concentrations, with a brain to plasma ratio of 15.8. The rodent data 319 presented here supports the model prediction of a higher concentration of efavirenz in brain tissue, 320 with a median tissue to plasma ratio of 9.5. Recently, efavirenz has been demonstrated to accumulate 321 in the brain tissue of a macaque. Following 8 days of orally administered efavirenz (60 mg kg -1 ) the 322 concentrations in plasma and CSF were 541 and 3.30 ng mL -1 respectively. Concentrations of 323 efavirenz in the cerebellum and basal ganglia were 6.86 µg g -1 (tissue to plasma ratio 12.7) and 2.01 324 µg g -1 (tissue to plasma ratio 3.7) respectively (27). 325
326
Currently only one study has examined efavirenz concentrations in human brain tissue (28). This 327 study showed similar brain concentrations to historical CSF values and are in disagreement with the 328 data presented here. While participants in this analysis had efavirenz detectable in intracardiac serum 329 using a qualitative assay, reliable dosing information was not routinely available since the final care 330 setting varied between individuals (home, hospice, or hospital). Given this uncertainty regarding the 331 final dosing interval, no precise information was available on the time of last dose, which 332 complicates interpretation of the reported brain concentrations. If the last efavirenz dose was 333 administered, for example, 3 days prior to death, then the brain tissue concentrations may not 334 accurately reflect those that occur in living, adherent patients. However, efavirenz has been shown to 335 display long plasma half-life (40 to 52 hours) (29). This would indicate patients would have had 336 ceased receiving efavirenz for many days or having poor adherence in order to explain the very 337 low concentrations observed. Despite this the data predicted by the model is supported by robust 338 data generated from the brain tissue concentrations from rats and monkeys (27) . is the high degree of protein binding of efavirenz. In plasma, efavirenz is highly protein bound (fu 345 0.01) (31). Protein binding in the CSF is much lower leading to more free efavirenz, fu 0.238 (29) . 346 The data presented here from rapid equilibrium dialysis shows efavirenz fu in rodent brain tissue to 347 be 0.00197. Taken collectively, the combination of low fu and affinity for the lipophilic environment 348 of the brain favour accumulation of efavirenz in the CNS. Lipophilicity has been shown to be a 349 significant factor in uptake of drugs into the brain (32). Lipophilicity, but not plasma protein binding, 350 was shown to correlate with uptake of benzodiazepines, for example, into the brain. However, this 351 study did not consider fu in the brain and plasma fu may not be a good indicator of brain fu. Kalvass 352 et al examined the fu in plasma and brain tissue of 34 drugs covering multiple drug classes. The data 353 presented showed that plasma fu both under and overestimated brain fu depending on the drug (33). 354
355
Although this is the first study to employ PBPK modelling to investigate efavirenz distribution into 356 the CNS, PBPK has been used previously to investigate efavirenz dose optimisation, drug-drug 357 interactions and PK in special populations (19, 34) . 358
359
Limitations of this work include that the presented model does not take into account genetic 360 variability (i.e. CYP2B6 variants), the brain fu values were generated in rodent brain rather than 361 human brain, the current model is not able to estimate local concentrations in individual brain 362 regions, and permeability of efavirenz was calculated using a QSAR model of passive permeability 363 which often rely on extrapolated data from animals with important differences to humans (21, 35) . 364 The assumption that the permeability of the two barriers is equal may be incorrect. However, these 369 aspects could be expanded in future modelling strategies as the necessary input data emerges. 370
The BBB is highly effective at excluding xenobiotics from the CNS. Tight cellular junctions prevent 371 paracellular transport of drugs and the metabolising enzymes and transport proteins remove drugs 372 from the CNS. As such, another potential limitation of the model that warrants further elaboration is 373 that distribution of efavirenz across the BBB may not be governed purely by passive permeability. 374
The potential influence of influx and efflux transporters was not considered because efavirenz is not 375 classified as substrate of any transporters and effects of transporters on efavirenz PK have not been 376 described. The model presented here potentially may be improved upon in the future if efavirenz is 377 demonstrated to be a substrate for such transporters. from Abbott, Merck, Tibotec, and GlaxoSmithKline. He has consulted for Gilead Sciences, 395
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